These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

485 related items for PubMed ID: 19201905

  • 1. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S, Nagato K, Kunii N, Yamamoto H, Yamasaki K, Okita K, Hanaoka H, Shimizu N, Suzuki M, Yoshino I, Taniguchi M, Fujisawa T, Nakayama T.
    J Immunol; 2009 Feb 15; 182(4):2492-501. PubMed ID: 19201905
    [Abstract] [Full Text] [Related]

  • 2. A phase I study of alpha-galactosylceramide (KRN7000)-pulsed dendritic cells in patients with advanced and recurrent non-small cell lung cancer.
    Ishikawa A, Motohashi S, Ishikawa E, Fuchida H, Higashino K, Otsuji M, Iizasa T, Nakayama T, Taniguchi M, Fujisawa T.
    Clin Cancer Res; 2005 Mar 01; 11(5):1910-7. PubMed ID: 15756017
    [Abstract] [Full Text] [Related]

  • 3. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL, Zisman A, Pantuck A, Calilliw R, Hernandez JM, Paik S, Nguyen D, Gitlitz B, Shintaku PI, de Kernion J, Figlin R, Belldegrun A.
    Cancer Res; 2001 Nov 01; 61(21):7925-33. PubMed ID: 11691814
    [Abstract] [Full Text] [Related]

  • 4. A phase I study of in vitro expanded natural killer T cells in patients with advanced and recurrent non-small cell lung cancer.
    Motohashi S, Ishikawa A, Ishikawa E, Otsuji M, Iizasa T, Hanaoka H, Shimizu N, Horiguchi S, Okamoto Y, Fujii S, Taniguchi M, Fujisawa T, Nakayama T.
    Clin Cancer Res; 2006 Oct 15; 12(20 Pt 1):6079-86. PubMed ID: 17028247
    [Abstract] [Full Text] [Related]

  • 5. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
    Wang H, Zhou FJ, Wang QJ, Qin ZK, Huang LX, Liu ZW, Han H, Li YQ, Chen SP, Xia JC.
    Ai Zheng; 2006 May 15; 25(5):625-30. PubMed ID: 16687087
    [Abstract] [Full Text] [Related]

  • 6. Combination therapy with tumor cell-pulsed dendritic cells and activated lymphocytes for patients with disseminated carcinomas.
    Katano M, Morisaki T, Koga K, Nakamura M, Onishi H, Matsumoto K, Tasaki A, Nakashima H, Akiyoshi T, Nakamura M.
    Anticancer Res; 2005 May 15; 25(6A):3771-6. PubMed ID: 16302738
    [Abstract] [Full Text] [Related]

  • 7. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors.
    Giaccone G, Punt CJ, Ando Y, Ruijter R, Nishi N, Peters M, von Blomberg BM, Scheper RJ, van der Vliet HJ, van den Eertwegh AJ, Roelvink M, Beijnen J, Zwierzina H, Pinedo HM.
    Clin Cancer Res; 2002 Dec 15; 8(12):3702-9. PubMed ID: 12473579
    [Abstract] [Full Text] [Related]

  • 8. Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease.
    Hill HC, Conway TF, Sabel MS, Jong YS, Mathiowitz E, Bankert RB, Egilmez NK.
    Cancer Res; 2002 Dec 15; 62(24):7254-63. PubMed ID: 12499267
    [Abstract] [Full Text] [Related]

  • 9. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer.
    Sun Z, Shi L, Zhang H, Shao Y, Wang Y, Lin Y, Li X, Bai C.
    Clin Immunol; 2011 Jan 15; 138(1):23-32. PubMed ID: 21041120
    [Abstract] [Full Text] [Related]

  • 10. Granulocyte colony-stimulating factor suppresses autologous tumor killing activity of the peripheral blood lymphocytes in the patients with ovarian carcinoma.
    Ohta Y, Hayakawa S, Karasaki-Suzuki M, Sugita K, Komine S, Chishima F, Hatta Y, Horie T, Seo N, Sheikh A, Nemoto N, Yamamoto T.
    Am J Reprod Immunol; 2004 Jul 15; 52(1):81-7. PubMed ID: 15214947
    [Abstract] [Full Text] [Related]

  • 11. Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide.
    Bolonaki I, Kotsakis A, Papadimitraki E, Aggouraki D, Konsolakis G, Vagia A, Christophylakis C, Nikoloudi I, Magganas E, Galanis A, Cordopatis P, Kosmatopoulos K, Georgoulias V, Mavroudis D.
    J Clin Oncol; 2007 Jul 01; 25(19):2727-34. PubMed ID: 17602077
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
    Nemunaitis J, Dillman RO, Schwarzenberger PO, Senzer N, Cunningham C, Cutler J, Tong A, Kumar P, Pappen B, Hamilton C, DeVol E, Maples PB, Liu L, Chamberlin T, Shawler DL, Fakhrai H.
    J Clin Oncol; 2006 Oct 10; 24(29):4721-30. PubMed ID: 16966690
    [Abstract] [Full Text] [Related]

  • 13. A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma.
    Chang GC, Lan HC, Juang SH, Wu YC, Lee HC, Hung YM, Yang HY, Whang-Peng J, Liu KJ.
    Cancer; 2005 Feb 15; 103(4):763-71. PubMed ID: 15637694
    [Abstract] [Full Text] [Related]

  • 14. Induction of NKT cell-specific immune responses in cancer tissues after NKT cell-targeted adoptive immunotherapy.
    Yamasaki K, Horiguchi S, Kurosaki M, Kunii N, Nagato K, Hanaoka H, Shimizu N, Ueno N, Yamamoto S, Taniguchi M, Motohashi S, Nakayama T, Okamoto Y.
    Clin Immunol; 2011 Mar 15; 138(3):255-65. PubMed ID: 21185787
    [Abstract] [Full Text] [Related]

  • 15. Clinical and immunological effects of granulocyte-macrophage colony-stimulating factor coadministered with interleukin 2: a phase IB study.
    Schiller JH, Hank JA, Khorsand M, Storer B, Borchert A, Huseby-Moore K, Burns D, Wesly O, Albertini MR, Wilding G, Sondel PM.
    Clin Cancer Res; 1996 Feb 15; 2(2):319-30. PubMed ID: 9816175
    [Abstract] [Full Text] [Related]

  • 16. Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein.
    Ebina T, Fujimiya Y.
    Lung Cancer; 2008 May 15; 60(2):246-51. PubMed ID: 17980454
    [Abstract] [Full Text] [Related]

  • 17. A phase I study of loco-regional immunotherapy by transbronchial injection of α-galactosylceramide-pulsed antigen presenting cells in patients with lung cancer.
    Ishibashi F, Sakairi Y, Iwata T, Moriya Y, Mizobuchi T, Hoshino H, Yoshida S, Hanaoka H, Yoshino I, Motohashi S.
    Clin Immunol; 2020 Jun 15; 215():108457. PubMed ID: 32387537
    [Abstract] [Full Text] [Related]

  • 18. Dendritic cell maturation by CD11c- T cells and Valpha24+ natural killer T-cell activation by alpha-galactosylceramide.
    Ishikawa E, Motohashi S, Ishikawa A, Ito T, Uchida T, Kaneko T, Tanaka Y, Horiguchi S, Okamoto Y, Fujisawa T, Tsuboi K, Taniguchi M, Matsumura A, Nakayama T.
    Int J Cancer; 2005 Nov 01; 117(2):265-73. PubMed ID: 15900581
    [Abstract] [Full Text] [Related]

  • 19. An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
    Meyer RG, Korn S, Micke P, Becker K, Huber C, Wölfel T, Buhl R.
    Lung Cancer; 2007 Oct 01; 58(1):88-94. PubMed ID: 17599645
    [Abstract] [Full Text] [Related]

  • 20. Induction of CD8 T-cell-Ifn-gamma response and positive clinical outcome after immunization with gene-modified allogeneic tumor cells in advanced non-small-cell lung carcinoma.
    Raez LE, Cassileth PA, Schlesselman JJ, Padmanabhan S, Fisher EZ, Baldie PA, Sridhar K, Podack ER.
    Cancer Gene Ther; 2003 Nov 01; 10(11):850-8. PubMed ID: 14605671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.